📰 Toby Maher News
Page 5 - Toby Maher News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Toby Maher. Real-time updates on events, politics, business and more.
February 10, 2022
/PRNewswire/ -- Vicore Pharma Holding AB (publ) ("Vicore"), a clinical-stage pharmaceutical company developing medicines targeting the angiotensin II type 2...
February 10, 2022
/PRNewswire/ -- Vicore Pharma Holding AB (publ) ("Vicore"), a clinical-stage pharmaceutical company developing medicines targeting the angiotensin II type 2...
February 10, 2022
GOTHENBURG, Sweden, Feb. 10, 2022 /PRNewswire/ -- Vicore Pharma Holding AB (publ) ("Vicore"), a clinical-stage pharmaceutical company developing medicines targeting the angiotensin II type 2
February 10, 2022
/PRNewswire/ -- Vicore Pharma Holding AB (publ) ("Vicore"), a clinical-stage pharmaceutical company developing medicines targeting the angiotensin II type 2...
January 6, 2022
Investegate announcements from PureTech Health PLC, LYT-100 Shows Improved AE Profile vs Pirfenidone
October 11, 2021
Investegate announcements from Redx Pharma plc, R&D Day and New Clinical Data for ROCK2 Inhibitor
September 22, 2021
/PRNewswire/ -- Vicore Pharma Holding AB (publ) ("Vicore"), a rare disease pharmaceutical company developing innovative medicines for severe lung disorders...
September 22, 2021
Webinar On Thursday, September 30 @ 16:00 CET (10AM ET) With The Medical Doctors And IPF Experts Prof. Toby Maher and Prof. Joanna Porter. GOTHENBURG, Sweden, Sept. 22, 2021 /PRNewswire/
May 13, 2021
PureTech Forms Clinical Advisory Board for Idiopathic Pulmonary Fibrosis and Related Lung Disorders Leading experts in the field will advise on clinical development of PureTech’s lead, wholly-owned product candidate, LYT-100, in idiopathic pulmonary fibrosis and other progressive fibrosing interstitial lu...
May 12, 2021
PureTech Health plc: PureTech Forms Clinical Advisory Board for Idiopathic Pulmonary Fibrosis and Related Lung Disorders idiopathic pulmonary fibrosis and other progressive fibrosing interstitial lung diseases PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced the formation of its Clinical Adviso...